Research programme: rho kinase inhibitors - Charles River Laboratories
Latest Information Update: 22 Nov 2016
At a glance
- Originator Charles River Laboratories
- Class Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Huntington's disease
Most Recent Events
- 10 Nov 2016 Early research in Huntington's disease in USA